论文部分内容阅读
目的观察放疗联合替莫唑胺与单纯放疗相比治疗高级别胶质瘤术后患者的临床疗效及副反应。方法40例经病理证实为高级别脑胶质瘤患者随机分为观察组（A组）和对照组（B组）。 A组：放疗联合替莫唑胺化疗（Ⅲ级8例，Ⅳ级12例），放疗肿瘤剂量(DT)60Gy，同步替莫唑胺化疗，75mg/m2，共42d。放疗后1个月，替莫唑胺辅助化疗6周期。 B组：术后单纯放疗（Ⅲ级9例，Ⅳ级11例），放疗肿瘤剂量(DT)60Gy。结果 A组整体1年、2年、3年生存率分别为：90.00%（18/20）、80.00%（16/20）、15.00%（3/20）；B组70.00%（14/20）、35.00%（7/20）、10.00%（2/20）；中位生存时间（MST以月为单位）分别：为19.9个月、10.4个月。观察组2年生存率较对照组有统计学差别（=8.76，<0.05）。结论高级别脑胶质瘤术后放疗联合替莫唑胺化疗较单纯放疗可显著提高患者生存率，副反应可以耐受。“,”0bjective To retrospectively study the clinical ef ect of cerebral gliomas received radiotherapy and radiochemotherapy with temozolomide postoperatively.Methods 40 postoperative patients with erebral gliomass were postoperatively treated.B group (RT group)was ir adiated with DT60Gy merely and A group (RCT group)combined with chemotherapy (Temozolomide 75mg/m2.d after radiotherapy with 4~6 cycles of chemotherapy were treated (150~200mg/m2·d.Continued 5 days,per 28 days one cycle).Two groups were also treated with dexamethasone and lower ICP.Results The 1-,2-,and 3-year survival rate of patients of RCT group was 90.00%,80.00%and 15.00%,respectively.The1-,2-,and 3-year survival rate of patients of RT group Was 70.00%,35.00%and 10.00%, respectively.The dif erence of the survival rates between two groups was significant( <0.05).There was no significant dif erence in incidence of adverse reactions of two groups .Conclusion Concur ent chemoradiotherapy can significantlyprolong the disease free survival time of patients with cerebral gliomas af ter surgery ,without increasing side ef ects ,it's a bet er treatment for glioma surgery.